IJSDR
IJSDR
INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH
International Peer Reviewed & Refereed Journals, Open Access Journal
ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016
open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15

Issue: March 2024

Volume 9 | Issue 3

Impact factor: 8.15

Click Here For more Info

Imp Links for Author
Imp Links for Reviewer
Research Area
Subscribe IJSDR
Visitor Counter

Copyright Infringement Claims
Indexing Partner
Published Paper Details
Paper Title: THE EFFECT OF CAPMATINIB FOR THE TREATMENT OF MET AMPLIFIED NON SMALL CELL LUNG CANCER
Authors Name: Dr. R Dinesh Kumar , Christina Ponnachen , Bivishya R , Jormy John
Unique Id: IJSDR2108018
Published In: Volume 6 Issue 8, August-2021
Abstract: ABSTRACT PRINCIPLE: To assess the effect of capmatinib, a potent selective inhibitor of MET receptor among patients with non-small cell cancer (NSCLC) with MET dysregulation Among patients with non–small-cell lung cancer (NSCLC), MET amplifications occur in 1 to 6%. METHODS: A multiple-cohort, phase 2 study was conducted evaluating capmatinib in patients with MET-dysregulated advanced NSCLC. Patients were assigned to cohorts on the basis of previous lines of therapy and MET status (MET exon 14 skipping mutation or MET amplification according to gene copy number in tumour tissue). Patients received capmatinib (400-mg tablet) twice daily. The primary goal was to find the safety and efficacy of the drug, also to evaluate antitumour activity. RESULTS: The total date was collected and among patients with NSCLC with MET dysregulation, overall response showed improved survival within these patients. The most frequently reported adverse events were peripheral edema (in 51%) and nausea (in 45%); these events were mostly of grade 1 or 2. CONCLUSION: From the collected, we have concluded that capmatinib showed substantial antitumour activity in NSCLC with MET dysregulation. Low-grade peripheral edema and nausea were the main toxic effect.
Keywords: Capmatinib, Non small cell lung cancer, MET amplication.
Cite Article: "THE EFFECT OF CAPMATINIB FOR THE TREATMENT OF MET AMPLIFIED NON SMALL CELL LUNG CANCER", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.6, Issue 8, page no.106 - 111, August-2021, Available :http://www.ijsdr.org/papers/IJSDR2108018.pdf
Downloads: 000336256
Publication Details: Published Paper ID: IJSDR2108018
Registration ID:193598
Published In: Volume 6 Issue 8, August-2021
DOI (Digital Object Identifier):
Page No: 106 - 111
Publisher: IJSDR | www.ijsdr.org
ISSN Number: 2455-2631

Click Here to Download This Article

Article Preview

Click here for Article Preview







Major Indexing from www.ijsdr.org
Google Scholar ResearcherID Thomson Reuters Mendeley : reference manager Academia.edu
arXiv.org : cornell university library Research Gate CiteSeerX DOAJ : Directory of Open Access Journals
DRJI Index Copernicus International Scribd DocStoc

Track Paper
Important Links
Conference Proposal
ISSN
DOI (A digital object identifier)


Providing A digital object identifier by DOI
How to GET DOI and Hard Copy Related
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Creative Commons License
This material is Open Knowledge
This material is Open Data
This material is Open Content
Social Media
IJSDR

Indexing Partner